	US 11,921,120 B2
	Compositions and methods for identifying and modulating metabolic health
John F. Rawls, Chapel Hill, NC (US); and James E. N. Minchin, Chapel Hill, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Mar. 14, 2021, as Appl. No. 17/200,886.
Application 17/200,886 is a division of application No. 15/558,889, previously published as PCT/US2016/022958, filed on Mar. 17, 2016.
Claims priority of provisional application 62/134,161, filed on Mar. 17, 2015.
Prior Publication US 2021/0278419 A1, Sep. 9, 2021
Int. Cl. G01N 33/68 (2006.01); A61K 38/26 (2006.01); A61K 38/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)

CPC G01N 33/6893 (2013.01) [A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); G01N 2800/042 (2013.01)]

12 Claims

1. A method of identifying a subject at risk for metabolic dysfunction, the method comprising:

(a) isolating a biosample from a subject;

(b) determining the level of one or more biomarkers present in the biosample, wherein the one or more biomarkers comprise

PlexinD1 nucleic acid or protein,

COL5A1 nucleic acid or protein, or

a combination thereof;

(c) identifying the subject as having a risk for metabolic dysfunction when the level of the one or more biomarkers is increased or decreased relative to a reference level or a range of reference levels of the same biomarker, and wherein the metabolic dysfunction is insulin sensitivity, insulin resistance, or type 2 diabetes; and

(d) treating the at-risk subject by administering to the subject an interfering molecule that (i) decreases the level or activity of the PlexinD1 nucleic acid or protein, or (ii) increases the level or activity of the COL5A1 nucleic acid or protein.